Nal-IRI + 5-FU/LV (PDAC, 2L nanoliposomal irinotecan)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-NAL-IRI DRUG-LEUCOVORIN DRUG-5-FLUOROURACIL |
|---|
| ID | REG-NAL-IRI-5FU-LV-PDAC |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | None declared |
Used By
Drug
DRUG-NAL-IRI- Nanoliposomal irinotecan
Indication
IND-PDAC-METASTATIC-2L-NAL-IRI- IND-PDAC-METASTATIC-2L-NAL-IRI